Health Economics›Prostate cancer›Definitive therapy including active surveillance

Definitive therapy including active surveillance

Prostate cancer · 6 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Flutamide, Leuprolide, RT Variant #01	—	R 19 156	28d	—	~178.8 mo	~4	~R 40 363 PFS proxy · indirect	1
Flutamide, Goserelin, RT Variant #01	—	R 3 653	28d	—	—	~2	~R 7 306 PFS proxy · indirect	2
Goserelin and RT Variant #01	—	R 584	90d	—	—	~2	~R 1 168 PFS proxy · indirect	1
ADT Variant #01 Partial	—	—	—	—	~52.0 mo	~1	—	15
ADT and RT Variant #01 Partial	—	—	56d	—	~105.8 mo	~1	—	3
Active surveillance Partial	—	—	—	—	—	—	—	1

6 of 6 regimens shown